A double-blind, randomized, placebo-controlled, multicenter study investigating the efficacy and tolerability of Angeliq (drospirenone 2mg and estradiol 1mg) [estradiol/drospirenone] in postmenopausal Chinese women with vasomotor symptoms over four 28-day treatment cycles.

Trial Profile

A double-blind, randomized, placebo-controlled, multicenter study investigating the efficacy and tolerability of Angeliq (drospirenone 2mg and estradiol 1mg) [estradiol/drospirenone] in postmenopausal Chinese women with vasomotor symptoms over four 28-day treatment cycles.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2013

At a glance

  • Drugs Estradiol/drospirenone (Primary)
  • Indications Hot flashes; Menopausal syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 06 Apr 2011 Results published in Climacteric.
    • 26 May 2008 Status changed from recruiting to completed, reported by ClinicalTrials.gov.
    • 27 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top